Pulse Biosciences 3Q 2026: Revenue $395K, EPS ($0.32) — 10-Q Summary

Pulse Biosciences’ revenue rose year over year, while its net loss widened. Revenue reflected limited-market-release sales of the Vybrance Percutaneous Electrode System; higher clinical research and professional-services costs and employee-related expenses drove the increase in research and develop…